Sars-Cov-2 Neutralization Antibody Rapid Test – Product code: SC-1569-20
The SARS-CoV-2 Neutralizing Antibody Rapid Test Cassette (Whole Blood/Serum/Plasma) is a rapid immunochromatographic test designed for the qualitative detection of neutralizing antibodies against SARS-CoV-2 that block the interaction between the domain that binds the viral spike glycoprotein receptor (RBD) and cell surface receptor ACE2 in human serum, plasma or whole blood. It is intended to be used as an aid in the identification of individuals with an adaptive immune response to SARS-CoV-2. This test should not be used to diagnose acute SARS-CoV-2 infection. The results indicate the detection of neutralizing SARS-CoV-2 antibodies. Positive results indicate the presence of neutralizing SARS-CoV-2 antibodies. The new coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. It mainly affects humans. Patients infected with the new coronavirus are currently the main source of infection; even asymptomatic infected individuals can be a source of infection. According to the latest epidemiological studies, the incubation period ranges from 1 to 14 days, and is mainly concentrated between the 3rd and 7th day. The most common manifestations include fever, fatigue, and dry cough. Nasal congestion, runny nose, sore throat, myalgia, and diarrhea are also present in some cases. All coronaviruses share similarities in the organization and expression of their genome, 16 non-structural proteins (nsp1 to nsp16), encoded by open reading frames (ORF) 1a/b at the 5 ‘end, are followed by the peak structural (S), envelope (E), membrane (M) and nucleocapsid (N) proteins, encoded by other ORFs at the end of the 3 ‘. virus gains access to the host cell through binding of the protein S receptor binding domain (RBD) to the angiotensin converting enzyme 2 (ACE2) receptor on target cells, particularly respiratory epithelial cells of the guest. Following SARS-CoV-2 infection, the host usually triggers an immune response against the virus by producing various types of antibodies in the blood. A subset of these antibodies, which reduce viral infection by binding to the surface epitopes of the virus particles, blocking their entry into the infected cell, are called neutralizing antibodies (NAbs). This assay contains two key components: the recombinant RBD SARS-CoV-2 fragment, labeled with colloidal gold, as tracers; and human ACE2 receptor protein (hACE2), coated with a cellulose nitrate membrane. When samples are added to Sample Buffer, neutralizing antibodies, if present in the sample, will bind to the RBD-labeled colloidal gold and block the protein interaction between RBD and hACE2. Unbound RBD-labeled colloidal gold as well as any RBD-labeled colloidal gold bound to non-neutralizing antibody will be captured on the test line. The control line acts as a procedural quality control.